- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.04. | CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.04. | Rodman & Renshaw stuft CAMP4 Therapeutics mit "Buy" ein und sieht 55 % Potenzial | 1 | Investing.com Deutsch | ||
| 14.04. | Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating | 2 | Investing.com | ||
| 02.04. | Leerink raises CAMP4 Therapeutics price target on CMP-002 progress | 1 | Investing.com | ||
| 02.04. | Fortschritte bei CMP-002: Leerink erhöht Kursziel für CAMP4 Therapeutics | 4 | Investing.com Deutsch | ||
| 24.03. | CAMP4 verstärkt Verwaltungsrat mit Finanzexperte Michael MacLean | 3 | Investing.com Deutsch | ||
| 24.03. | CAMP4 Therapeutics appoints Michael MacLean to board of directors | 2 | Investing.com | ||
| 24.03. | CAMP4 Therapeutics: CAMP4 Appoints Michael MacLean to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 24.03. | Camp4 Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 06.03. | Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target | 4 | Investing.com | ||
| 05.03. | Camp4 Therapeutics GAAP EPS of -$2.65 misses by $0.77, revenue of $3.5M in-line | 3 | Seeking Alpha | ||
| 05.03. | Camp4 Therapeutics Earnings Review: Q4 Summary | 1 | Benzinga.com | ||
| 05.03. | Camp4 Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 05.03. | Camp4 Therapeutics Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | CAMP4 Therapeutics: CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights | 398 | GlobeNewswire (Europe) | GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance... ► Artikel lesen | |
| 05.03. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 20.02. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 16.01. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 19.12.25 | GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst | 7 | Benzinga.com | ||
| 18.12.25 | CAMP4 Therapeutics Teams With GSK On ASO Drug Candidates | 549 | AFX News | LONDON (dpa-AFX) - CAMP4 Therapeutics Corporation (CAMP) on Thursday said it has entered into a strategic research, collaboration and license agreement with GSK to develop antisense oligonucleotide... ► Artikel lesen |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,080 | -0,81 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 21,490 | -4,40 % | Erasca, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 11,260 | +1,67 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| RELAY THERAPEUTICS | 15,130 | +0,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,105 | -10,13 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,760 | -0,43 % | Stifel reiterates Tango Therapeutics stock rating on combo potential | ||
| EVOTEC | 5,350 | -0,93 % | RBC stuft Evotec auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Evotec auf "Outperform" mit einem Kursziel von 10 Euro belassen. Charles Weston passte seine Prognosen und das Bewertungsmodell... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,700 | -1,80 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 5,020 | +24,57 % | What's Going On With Enveric Biosciences Stock On Friday? | ||
| NUVALENT | 104,53 | -3,28 % | Nuvalent präsentiert AACR-Daten vor PDUFA-Entscheid im September | ||
| BIONTECH | 90,15 | +0,22 % | Durchbruch in der Psychotherapie: Emyria meldet 50% Remission - Ein neuer "BioNTech-Moment" für die Mental-Health-Branche? | ||
| FIRST TRACKS BIOTHERAPEUTICS | 18,160 | -4,47 % | AnaptysBio, Inc.: Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations | Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately... ► Artikel lesen | |
| MAPLIGHT THERAPEUTICS | 29,760 | +2,62 % | MapLight Therapeutics, Inc.: MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004... ► Artikel lesen |
CAMP4 THERAPEUTICS CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,490 Euro und damit +1,35 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.